Infant Hearing Loss Clinical Trials

Find Infant Hearing Loss Clinical Trials Near You

Evaluation of Alpha-Tectorin, Interleukin-10, and Thiol-Disulfide Homeostasis in Individuals With Congenital Hearing Loss

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Congenital hearing loss is one of the most common sensory disorders of childhood, and the structural, immunologic and oxidative mechanisms involved in its development are incompletely understood. This case-control study aims to evaluate serum alpha-tectorin and interleukin-10 (IL-10) levels and thiol-disulfide homeostasis in children with congenital sensorineural hearing loss (cochlear implant users and hearing aid users) compared with healthy children with normal hearing. The findings are expected to contribute to a better understanding of the mechanisms underlying congenital hearing loss and to the identification of potential diagnostic and prognostic biomarkers.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 17
Healthy Volunteers: t
View:

⁃ Congenital Hearing Loss Groups (Cochlear Implant Group and Hearing Aid Group)

• Age under 18 years

• Congenital sensorineural hearing loss diagnosed at the Otorhinolaryngology outpatient clinic and confirmed by audiological testing (auditory brainstem response, otoacoustic emissions and/or pure-tone audiometry)

• Active use of a cochlear implant (Cochlear Implant Group) or active use of a hearing aid without cochlear implantation (Hearing Aid Group)

• No condition preventing collection of a peripheral blood sample

• Written informed consent from the parent or legal guardian

⁃ Healthy Control Group

• Age under 18 years

• No diagnosis of hearing loss and normal audiological evaluation

• No condition preventing collection of a peripheral blood sample

• Written informed consent from the parent or legal guardian

Locations
Other Locations
Turkey
Harran University Faculty of Medicine Hospital, Department of Otorhinolaryngology
RECRUITING
Sanliurfa
Contact Information
Primary
Kemal Özgen, MD
kemal.ozgen47@harran.edu.tr
+905422272347
Time Frame
Start Date: 2026-04-20
Estimated Completion Date: 2027-04
Participants
Target number of participants: 120
Treatments
Cochlear Implant Group
Children under 18 years of age with audiologically confirmed congenital sensorineural hearing loss who have undergone cochlear implantation and actively use the implant (n=40).
Hearing Aid Group
Children under 18 years of age with audiologically confirmed congenital sensorineural hearing loss who have not undergone cochlear implantation and actively use hearing aids (n=40).
Healthy Control Group
Age- and sex-matched healthy children under 18 years of age with normal audiological evaluation and no history of hearing loss (n=40).
Related Therapeutic Areas
Sponsors
Leads: Harran University

This content was sourced from clinicaltrials.gov